Karyopharm Therapeutics Inc.

NasdaqGS:KPTI Stock Report

Market Cap: US$96.9m

Karyopharm Therapeutics Dividends and Buybacks

Dividend criteria checks 0/6

Karyopharm Therapeutics does not have a record of paying a dividend.

Key information

n/a

Dividend yield

-1.1%

Buyback Yield

Total Shareholder Yield-1.1%
Future Dividend Yieldn/a
Dividend Growthn/a
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Payout ration/a

Recent dividend and buyback updates

No updates

Recent updates

Why Investors Shouldn't Be Surprised By Karyopharm Therapeutics Inc.'s (NASDAQ:KPTI) Low P/S

Oct 01
Why Investors Shouldn't Be Surprised By Karyopharm Therapeutics Inc.'s (NASDAQ:KPTI) Low P/S

Karyopharm Therapeutics Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Aug 09
Karyopharm Therapeutics Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Benign Growth For Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Underpins Stock's 28% Plummet

Apr 27
Benign Growth For Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Underpins Stock's 28% Plummet

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Held Back By Insufficient Growth Even After Shares Climb 33%

Feb 23
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Held Back By Insufficient Growth Even After Shares Climb 33%

Karyopharm: Approaching The Bottom Ahead Of Earnings And Topline Data (Rating Upgrade)

Feb 05

Improved Revenues Required Before Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Stock's 27% Jump Looks Justified

Apr 17
Improved Revenues Required Before Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Stock's 27% Jump Looks Justified

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Surges 27% Yet Its Low P/S Is No Reason For Excitement

Apr 17
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Surges 27% Yet Its Low P/S Is No Reason For Excitement

Karyopharm: Market Is Overlooking Growth

Oct 07

Karyopharm Therapeutics Q2 2022 Earnings Preview

Aug 03

Karyopharm cancer therapy eltanexor gets FDA fast track status, orphan drug tag in EU

Jul 20

Karyopharm: Another 2 Year Wait For Data

May 05

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if KPTI's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if KPTI's dividend payments have been increasing.


Dividend Yield vs Market

Karyopharm Therapeutics Dividend Yield vs Market
How does KPTI dividend yield compare to the market?
SegmentDividend Yield
Company (KPTI)n/a
Market Bottom 25% (US)1.4%
Market Top 25% (US)4.3%
Industry Average (Biotechs)2.3%
Analyst forecast (KPTI) (up to 3 years)n/a

Notable Dividend: Unable to evaluate KPTI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate KPTI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate KPTI's payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as KPTI has not reported any payouts.


Discover strong dividend paying companies